Wrongful termination: Lessons from the geron clinical trial

Stem Cells Translational Medicine

Volumn 3, Issue 12, 2014, Pages 1398-1401

  Scott, Christopher Thomas ^a   Magnus, David ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL RESEARCH; FINANCIAL MANAGEMENT; FUNDING; HUMAN; NONHUMAN; OLIGODENDROGLIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SPINAL CORD INJURY; STEM CELL TRANSPLANTATION; THERAPEUTIC MISCONCEPTION; TUMOR GROWTH; CLINICAL TRIAL (TOPIC); EMBRYONIC STEM CELL; ETHICS; FEMALE; MALE;

CLINICAL TRIALS AS TOPIC; EMBRYONIC STEM CELLS; ETHICS; FEMALE; HUMANS; MALE; SPINAL CORD INJURIES; STEM CELL TRANSPLANTATION;

EID: 84913587253     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2014-0147     Document Type: Article

References (28)

1. Moran N. hESC therapy pioneer Geron abandons stem cell R&D. Bio World. Available at http://www.bioworld.com/content/hesc-therapy-pioneer-geron-abandons-stem-cell-rd-1. Accessed January 18, 2013.
2. Geron to focus on its novel cancer programs. Available at http://ir.geron.com/phoenix.zhtml?c=67323&p=irol-newsArticle&ID=1635764&highlight. Accessed January 18, 2013.
3. Spinal cord injury trials program. Available at http://med.stanford.edu/news/all-news/2011/11/stanfordscvmc-team-treats-final-patient-in-landmark-stem-cell-therapy-trial.html. Accessed January 18, 2013.
4. Kimmelman J, Baylis F, Glass KC. Stem cell trials: Lessons from gene transfer research. Hastings Cent Rep 2006;36:23–26.
5. Thomson JA, Itskovitz-Eldor J, Shapiro SS et al. Embryonic stem cell lines derived from human blastocysts. Science 1998;282:1145–1147.
6. Conger K. Stanford/SCVMC team treats final patient in landmark stem cell therapy trial. Available at http://med.stanford.edu/ism/2011/november/geron.html. Accessed January 18, 2013.
7. Brown S. BioTime acquires stemcell assets from Geron, raises $10 million. San Francisco Business Times. Available at http://www.bizjournals.com/sanfrancisco/blog/biotech/2013/01/biotime-acquires-stem-cell-assets-geron.html. Accessed January 18, 2013.
8. Asterias biotherapeutics announces new results from first-in-man clinical trial. Available at http://asteriasbiotherapeutics.com/asterias-biotherapeutics-inc-announces-new-results-from-first-in-man-clinical-trial-of-a-cell-therapy-derived-from-embryonic-stem-cells/. Accessed May 25, 2014.
9. Asterias biotherapeutics. Available at http://www.cirm.ca.gov/our-progress/institutions/asterias-biotherapeutics. Accessed June 1, 2014.
10. World Medical Association General Assembly. Declaration of Helsinki: Ethical medical principles for medicalresearchinvolving human subjects. JAMA 2000;284:3043–3045.
11. Scott CT. Stem cells: New frontiers of ethics, law, and policy. Neurosurg Focus 2008; 24:E24.
12. Illes J, Reimer JC, Kwon BK. Stem cell clinical trials for spinal cord injury: Readiness, reluctance, redefinition. Stem Cell Rev 2011;7: 997–1005.
13. Baylis F. Geron’s discontinued stem cell trial: What about the research participants? The Hastings Center Bioethics Forum Available at http://www.thehastingscenter.org/Bioethicsforum/Post.aspx?id=5640&blogid=140&. Accessed January 31, 2013.
14. Eaton ML, Kwon BK, Scott CT. Money and Morals: Stopping clinical trials for financial reasons. Curr Top Behav Neurosci 2014 [Epub ahead of print].
15. Bretzner F, Gilbert F, Baylis F et al. Target populations for first-in-human embryonic stem cell research in spinal cord injury. Cell Stem Cell 2011;8:468–475.
16. Miller FG, Rosenstein DL. The therapeutic orientation to clinical trials. N Engl J Med 2003;348:1383–1386.
17. Dijkers MPJM. Quality of life of individuals with spinal cord injury: A review of conceptualization, measurement, and research findings. J Rehabil Res Dev 2005;42(suppl 1):87–110.
18. Neuralstem cell therapy for spinal cord injury. Available at http://www.neuralstem.com/cell-therapy-for-sci. Accessed July 7, 2014.
19. Iltis AS. Stopping trials early for commercial reasons: The risk-benefit relationship as a moral compass. J Med Ethics 2005; 31:410–414.
20. Magnus D. Translating stem cell research: Challenges at the research frontier. J Law Med Ethics 2010;38:267–276.
21. Gawrylewski A. Stem cell trial nearly a go? The Scientist. Available at http://www.the-scientist.com/?articles.view/articleNo/26829/title/Stem-cell-trial-nearly-a-go-/. Accessed January 18, 2013.
22. Scott C, Huggett B. Geron’s quixotic fate. Nat Biotechnol 2012;30:497.
23. Boyd K. Commentary: Early discontinuation violates Helsinki principles. BMJ 2001;322: 605–606.
24. Evans S, Pocock S. Societal responsibilities of clinical trial sponsors. BMJ 2001;322: 569–570.
25. Psaty BM, Rennie D. Stoppingmedical research to save money: A broken pact with researchers and patients. JAMA 2003;289:2128–2131.
26. United Nations Educational, Scientificand Cultural Organization (UNESCO). Report of the International Bioethics Committee of UNESCO (IBC) on consent. Available at http://unesdoc.unesco.org/images/0017/001781/178124e.pdf. Accessed September 29, 2013.
27. Appelbaum PS, Lidz CW. Twenty-five years of therapeutic misconception. Hastings Cent Rep 2008;38:5–6; author reply 6–7.
28. Henderson GE. Is informed consent broken? Am J Med Sci 2011;342:267–272.